Share Email Print
cover

Proceedings Paper

Catheter-based ultrasound hyperthermia with HDR brachytherapy for treatment of locally advanced cancer of the prostate and cervix
Author(s): Chris J. Diederich; Jeff Wootton; Punit Prakash; Vasant Salgaonkar; Titania Juang; Serena Scott; Xin Chen; Adam Cunha; Jean Pouliot; I. C. Hsu
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

A clinical treatment delivery platform has been developed and is being evaluated in a clinical pilot study for providing 3D controlled hyperthermia with catheter-based ultrasound applicators in conjunction with high dose rate (HDR) brachytherapy. Catheter-based ultrasound applicators are capable of 3D spatial control of heating in both angle and length of the devices, with enhanced radial penetration of heating compared to other hyperthermia technologies. Interstitial and endocavity ultrasound devices have been developed specifically for applying hyperthermia within HDR brachytherapy implants during radiation therapy in the treatment of cervix and prostate. A pilot study of the combination of catheter based ultrasound with HDR brachytherapy for locally advanced prostate and cervical cancer has been initiated, and preliminary results of the performance and heating distributions are reported herein. The treatment delivery platform consists of a 32 channel RF amplifier and a 48 channel thermocouple monitoring system. Controlling software can monitor and regulate frequency and power to each transducer section as required during the procedure. Interstitial applicators consist of multiple transducer sections of 2-4 cm length × 180 deg and 3-4 cm × 360 deg. heating patterns to be inserted in specific placed 13g implant catheters. The endocavity device, designed to be inserted within a 6 mm OD plastic tandem catheter within the cervix, consists of 2-3 transducers × dual 180 or 360 deg sectors. 3D temperature based treatment planning and optimization is dovetailed to the HDR optimization based planning to best configure and position the applicators within the catheters, and to determine optimal base power levels to each transducer section. To date we have treated eight cervix implants and six prostate implants. 100 % of treatments achieved a goal of >60 min duration, with therapeutic temperatures achieved in all cases. Thermal dosimetry within the hyperthermia target volume (HTV) and clinical target volume (CTV) are reported. Catheter-based ultrasound hyperthermia with HDR appears feasible with therapeutic temperature coverage of the target volume within the prostate or cervix while sparing surrounding more sensitive regions.

Paper Details

Date Published: 23 February 2011
PDF: 8 pages
Proc. SPIE 7901, Energy-based Treatment of Tissue and Assessment VI, 79010O (23 February 2011); doi: 10.1117/12.876401
Show Author Affiliations
Chris J. Diederich, Univ. of California, San Francisco (United States)
Univ. of California, Berkeley (United States)
Jeff Wootton, Univ. of California, San Francisco (United States)
Univ. of California, Berkeley (United States)
Punit Prakash, Univ. of California, San Francisco (United States)
Vasant Salgaonkar, Univ. of California, San Francisco (United States)
Titania Juang, Univ. of California, San Francisco (United States)
Serena Scott, Univ. of California, San Francisco (United States)
Univ. of California, Berkeley (United States)
Xin Chen, Univ. of California, San Francisco (United States)
Adam Cunha, Univ. of California, San Francisco (United States)
Jean Pouliot, Univ. of California, San Francisco (United States)
I. C. Hsu, Univ. of California, San Francisco (United States)


Published in SPIE Proceedings Vol. 7901:
Energy-based Treatment of Tissue and Assessment VI
Thomas P. Ryan, Editor(s)

© SPIE. Terms of Use
Back to Top